Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group

被引:9
|
作者
Shimada, Y
Akane, H
Taniguchi, N
Matsuhisa, A
Kawano, N
Kikuchi, K
Yatsu, T
Tahara, A
Tomura, Y
Kusayama, T
Wada, K
Tsukada, J
Tsunoda, T
Tanaka, A
机构
[1] Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan
[2] Yamanouchi Pharmaceut Co Ltd, Clin Dev Dept, Itabashi Ku, Tokyo 1748612, Japan
[3] Yamanouchi Pharmaceut Co Ltd, Chem Technol Lab, Ibaraki 3180001, Japan
[4] Yamanouchi Pharmaceut Co Ltd, Corp Commun Dept, Chuo Ku, Tokyo 1038411, Japan
关键词
arginine vasopressin; V-1A receptor selective antagonist; 2-ethyl-1H-1-imidazole;
D O I
10.1248/cpb.53.764
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To find a new series of arginine vasopressin (AV]P) VIA receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide (7) was investigated. Replacement of the 2-phenyl group by a 2-ethyl-1H-imidazol-1-yl group was effective in yielding a V-IA-selective compound. Moreover, this imidazolyl group was introduced in the same position in YM-35471 (6), and further studies of these compounds were performed. Consequently, we found that the (Z)-4'-({4,4-difluoro-5-[(N-cyclo-propylcarbamoyl)methylenel-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1-imidazol-1- yl)benzanilide (9f) exhibited highly potent affinity and selectivity, and was the most potent antagonist for the V,A receptor among our compounds. The synthesis and pharmacological evaluation of these compounds are described in this paper.
引用
收藏
页码:764 / 769
页数:6
相关论文
共 50 条
  • [31] Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist
    Tsukada, J
    Tahara, A
    Tomura, Y
    Kusayama, T
    Wada, K
    Ishii, N
    Taniguchi, N
    Suzuki, T
    Yatsu, T
    Uchida, W
    Shibasaki, M
    VASCULAR PHARMACOLOGY, 2005, 42 (02) : 47 - 55
  • [32] Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
    Tsukuda, J
    Tahara, A
    Tomura, Y
    Wada, K
    Kusayama, T
    Ishii, N
    Aoki, M
    Yatsu, T
    Uchida, W
    Taniguchi, N
    Tanaka, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 446 (1-3) : 129 - 138
  • [33] Bridged bicyclic vasopressin receptor antagonists with V2-selective or dual V1a/V2 activity (vol 12, pg 3081, 2002)
    Dyatkin, AB
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Gunnet, JW
    Hageman, W
    Look, R
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (12) : 3363 - 3363
  • [34] Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Gieldon, A
    Kazmierkiewicz, R
    Slusarz, R
    Ciarkowski, J
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2001, 15 (12) : 1085 - 1104
  • [35] Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Artur Giełdoń
    Rajmund Kaźmierkiewicz
    Rafał Ślusarz
    Jerzy Ciarkowski
    Journal of Computer-Aided Molecular Design, 2001, 15 : 1085 - 1104
  • [36] 2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists
    Urbanski, MJ
    Chen, RH
    Demarest, KT
    Gunnet, J
    Look, R
    Ericson, E
    Murray, WV
    Rybczynski, PJ
    Zhang, XY
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) : 4031 - 4034
  • [37] HIGHLY POTENT 1-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID SUBSTITUTED V2 AGONISTS OF ARGININE VASOPRESSIN (AVP)
    Kowalczyk, W.
    Derdowska, I.
    Prahl, A.
    Dawidowska, O.
    Slaninova, J.
    Lammek, B.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 250 - 250
  • [38] EARLY ADMINISTRATION OF THE SELECTIVE V1A RECEPTOR AGONIST SELEPRESSIN IS SUPERIOR TO ARGININE VASOPRESSIN OR NOREPINEPHRINE IN A SHEEP MODEL OF SEPTIC SHOCK
    Su, Fuhong
    He, Xinrong
    Taccone, Fabio Silvio
    Xie, Keliang
    Mouhamed, Moussa
    Kjolbye, Anne Louise
    Laporte, Regent
    Reinheimer, Torsten
    Vincent, Jean-Louis
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U41 - U41
  • [39] Differentiation of Arginine Vasopressin Antagonistic Effects by Selective V2 versus Dual V2/V1a Receptor Blockade in a Preclinical Heart Failure Model
    Mondritzki, Thomas
    Kolkhof, Peter
    Sabbah, Hani N.
    Gheorghiade, Mihai
    Fuerstner, Chantal
    Schmeck, Carsten
    Siedentop, Harald
    Schaefer, Stefan
    Truebel, Hubert
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (01) : 31 - 37
  • [40] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69